HC Wainwright & Co. Upgrades Black Diamond Therapeutic to Buy, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has upgraded Black Diamond Therapeutic (NASDAQ:BDTX) from Neutral to Buy, while maintaining the $11 price target.
June 28, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutic has been upgraded from Neutral to Buy by HC Wainwright & Co., with a maintained price target of $11.
The upgrade from Neutral to Buy indicates a positive outlook for Black Diamond Therapeutic. This could lead to increased investor interest and potentially a rise in the stock price. The maintained price target of $11 suggests that the analyst believes the stock is currently undervalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100